ERB 041 |
Catalog No.GC10389 |
ERB 041(ERB-041)은 강력하고 선택적인 에스트로겐 수용체(ER) β입니다. 인간, 쥐 및 마우스 ERβ에 대해 각각 5.4, 3.1 및 3.7nM의 IC50을 갖는 작용제. ERB 041은 ERβ에 대해 >200배 선택성을 표시합니다. ERα 이상;. ERB 041은 WNT/β-카테닌 신호 전달 경로를 약화시켜 작용하는 강력한 피부암 화학 예방제입니다. ERB 041은 난소암 세포자살을 유도합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 524684-52-4
Sample solution is provided at 25 µL, 10mM.
Prinaberel(ERB-041) is a potent and selective ERbeta agonist; being >200-fold selective for ERbeta.IC50 value:Target: ERbeta agonistin vitro: Treatment with ERβ selective estrogen agonists liquiritigenin and ERB-041 reduced the ability to invade a reconstituted basement membrane and to migrate in response to the cellular stimulus [1]. Pretreatment the PMs with ERB-041 resulted in a significant inhibition of LPS-induced iNOS expression and NF-kappaB activation by preventing its nuclear translocation [3].in vivo: Tumor numbers and volume were reduced by 60% and 84%, respectively, in the Erb-041-treated group as compared with UVB (alone) control. This inhibition in tumorigenesis was accompanied by the decrease in proliferating cell nuclear antigen (PCNA), cyclin D1, VEGF, and CD31, and an increase in apoptosis [2].
References:
[1]. Hinsche O, et al. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells. Int J Oncol. 2015 Feb;46(2):878-84.
[2]. Chaudhary SC, et al. Erb-041, an estrogen receptor-β agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014 Feb;7(2):186-98.
[3]. Xiu-li W, et al. ERB-041, a selective ER beta agonist, inhibits iNOS production in LPS-activated peritoneal macrophages of endometriosis via suppression of NF-kappaB activation. Mol Immunol. 2009 Jul;46(11-12):2413-8.
Average Rating: 5
(Based on Reviews and 6 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *